The evaluation discusses fifty eight peptides in various clinical phases, indicating a strong pipeline of peptide therapies concentrating on PPIs. These approaches open new avenues for treatment options tailored to beat unique breast cancer subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases. In this article, we https://henryv234ifc2.actoblog.com/profile